NCT01297764View on ClinicalTrials.gov

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone

"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40"

Trial Locations (1)

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Hackensack Meridian Health

OTHER

NCT01297764 - A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter